Incyte Reports Updated Results of Pemigatinib in P-II FIGHT-202 Trial for Patients with Previously Treated Advanced Cholangiocarcinoma

Shots:

• The P-II FIGHT-202 (NCT02924376) study involves assessing of pemigatinib (13.5 mg, qd) as monothx in adults patients previously treated, LA or metastatic cholangiocarcinoma with documented FGF/FGFR status divided into 3 cohorts: Cohort A (N=107, FGFR2 fusions or rearrangements), Cohort B (N=20, other FGF/FGFR genetic alterations) or Cohort C (N=18, no FGF/FGFR genetic alterations)  
• P-II FIGHT-202 results: ORR 36%, mDOR 7.5 mos., DCR 82%, mPFS 6.9mos., Preliminary OS 21.1mos., well-tolerated results; Presented at ESMO 2019  
• Pemigatinib is a selective oral inhibitor of FGFR isoforms 1, 2 and 3, also received FDA’s Breakthrough Therapy Designation for the treatment of previously treated, advanced/metastatic or unresectable FGFR2 translocated cholangiocarcinoma with its planned NDA submission to the US FDA before end of H2’19

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Behance